CWS
TGTX icon

Confluence Wealth Services’s TG Therapeutics TGTX Stock Holding History

Confluence Wealth Services’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-651
Closed -$12K – 1060
2021
Q4 		$12K Buy
+651
New +$16.9K ﹤0.01% 872

Other funds holding TGTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Confluence Wealth Services's TGTX Position: Q1 2022 in Review

Confluence Wealth Services sold out of TG Therapeutics (TGTX) in Q1 2022, closing a stake of 651 shares — an estimated $12K sold.

Confluence Wealth Services first reported a position in TGTX in Q4 2021 and held it in 1 quarter. The position peaked at $12K in Q4 2021. 181 funds tracked by Wall St. Rank hold TGTX as of Q1 2022.

  • Confluence Wealth Services reported no remaining TG Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Confluence Wealth Services sold 651 TG Therapeutics shares in Q1 2022, an estimated $12K.
  • Confluence Wealth Services first reported a position in TG Therapeutics in Q4 2021 and held it in 1 quarter.
  • Confluence Wealth Services's TG Therapeutics position peaked at $12K in Q4 2021.
  • 181 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2022.

Based on Confluence Wealth Services's 13F filing for Q1 2022, filed 26 Apr 2022.